Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents

Research output: Contribution to journalReview articlepeer-review

37 Scopus citations


Nephrogenic systemic fibrosis (NSF) is a disease seen exclusively in patients with decreased renal function. The use of gadolinium-based contrast agents (GBCAs) has a strong association with NSF. Linear non-ionic GBCAs that are more prone to release free gadolinium are the more likely to cause NSF. The number of reported cases has increased recently, and there are currently nine pediatric cases, the patients ranging in age from 8 years to 19 years, and the oldest adult patient is 87 years of age. The most successful treatment is improvement of renal function with renal transplantation or with recovery of acute kidney injury. NSF can be severely debilitating and even fatal. Avoidance of a GBCA in patients at risk, or limitation of the dose in the patients who need gadolinium enhancement, is recommended.

Original languageEnglish (US)
Pages (from-to)2121-2129
Number of pages9
JournalPediatric Nephrology
Issue number12
StatePublished - 2008


  • Contrast agents
  • End-stage renal disease
  • Gadolinium
  • Kidney disease
  • Magnetic resonance imaging
  • Nephrogenic systemic fibrosis

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Nephrology


Dive into the research topics of 'Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents'. Together they form a unique fingerprint.

Cite this